NCT05261529

Brief Summary

In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric, renal...), it has recently been proposed that 'health-related lifestyles' could have a determining role in balancing numerous organic processes at all levels. In line with this, the benefits of following a healthy dietary pattern such as the Mediterranean Diet and, specifically, the intake of Extra Virgin Olive Oil (EVOO) as well as the realization of regular physical exercise (PE) have been examined in numerous chronic non-communicable diseases such as obesity or cancer. However, in patients with autoimmune diseases, such as SLE, the possible effects of this synergy has not been investigated to date. Having demonstrated both the protective effect of a healthy dietary pattern and that of regular PE on the progression and risks associated with SLE in cross-sectional studies, non-intervention research has been developed that combines both strategies simultaneously, with nutritional supplementation or PE occurring independently. It is hypothesized that supplementation with EVOO in these patients together with PE will produce superior benefits compared to EVOO supplementation alone, showing changes in the phenotype of SLE and other parameters such as levels of chronicity/gravity, biomarkers (oxidative stress, immunological, inflammation), cardiovascular status and body composition.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 3, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 8, 2022

Completed
22 days until next milestone

First Posted

Study publicly available on registry

March 2, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

December 20, 2022

Status Verified

December 1, 2022

Enrollment Period

1.2 years

First QC Date

February 8, 2022

Last Update Submit

December 19, 2022

Conditions

Keywords

Mediterranean DietOlive OilPhysical ExerciseAutoimmune DiseasesSystemic Lupus ErythematosusMicrobiomeEpigenetcis

Outcome Measures

Primary Outcomes (1)

  • SLEDAI Systemic Lupus Erythematosus Disease Activity Index

    SLE-specific index that assess disease activity through a combination of data from clinical records, physical examination, organ-specific functional tests and serological studies.

    Participants will be followed over 24 weeks.

Secondary Outcomes (45)

  • Cumulative manifestations

    Participants will be followed over 24 weeks.

  • SLICC/ACR (Systemic Lupus International Collaborating clinics/American College of Rheumatology) Damage Index for Systemic Lupus Erythematosus.

    Participants will be followed over 24 weeks.

  • Pharmacological prescription

    Participants will be followed over 24 weeks.

  • Glucose level

    Participants will be followed over 24 weeks.

  • Urea level

    Participants will be followed over 24 weeks.

  • +40 more secondary outcomes

Study Arms (3)

Control Group

NO INTERVENTION

Control Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.

Oil Group

EXPERIMENTAL

Group with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.

Dietary Supplement: Extra Virgin Olive Oil (EVOO)

Oil + Exercise Group

EXPERIMENTAL

Group with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.

Dietary Supplement: Extra Virgin Olive Oil (EVOO)Behavioral: Physical Exercise Program

Interventions

Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.

Oil + Exercise GroupOil Group

Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.

Oil + Exercise Group

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Medium (8 to 11 points) to high (12 to 14 points) level of adherence to DM as measured by the 14-point DM adherence scale of the PREDIMED study.
  • Sedentary, inactive or non-performing subjects of structured PE (+5h sitting or doing less than 300min of weekly physical activity or \<60min structured exercise per week).

You may not qualify if:

  • Terminal stages of the disease
  • Serum creatinine levels ≥1.5mg / dl
  • Type 1 Diabetes Mellitus
  • Infection, trauma or surgery six months prior to intervention
  • SLICC\> 5
  • Pregnant, with intention, or breastfeeding
  • Diagnosis of other autoimmune / inflammatory diseases
  • Participation in other PE guided programs
  • Contraindication for PE: psychiatric or cognitive disorders, acute or chronic conditions (advanced lung disease, high requirements, stenosis\> 70%)
  • BMI of morbid obesity (≥40)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de Granada

Granada, Granada, Spain, 18016, Spain

RECRUITING

Related Publications (2)

  • Pocovi-Gerardino G, Correa-Rodriguez M, Callejas-Rubio JL, Rios-Fernandez R, Martin-Amada M, Cruz-Caparros MG, Rueda-Medina B, Ortego-Centeno N. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology (Oxford). 2021 Jan 5;60(1):160-169. doi: 10.1093/rheumatology/keaa210.

    PMID: 32594173BACKGROUND
  • Gil-Gutierrez R, Medina-Martinez I, Quesada-Caballero M, de la Hera-Fernandez FJ, Zamora-Pasadas M, Cantarero-Villanueva I, Albendin-Garcia L, Parola V, Rueda-Medina B, Correa-Rodriguez M. EFINUTRILES Study: Integrative Extra Virgin Olive Oil and Multimodal Lifestyle Interventions for Cardiovascular Health and SLE Management. Nutrients. 2025 Mar 19;17(6):1076. doi: 10.3390/nu17061076.

MeSH Terms

Conditions

Lupus Erythematosus, SystemicMotor ActivityAutoimmune Diseases

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesImmune System DiseasesBehavior

Study Officials

  • María Correa Rodríguez, Professor

    Universidad de Granada

    PRINCIPAL INVESTIGATOR

Central Study Contacts

María Corea Rodríguez, Professor

CONTACT

Blanca M Rueda Medina, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Participants randomly assigned in a 1:1:1 ratio to each of the three groups established through a centralized method with computer support (OxMaR software).
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Three-arm prospective randomized controlled 24-week clinical trial of patients diagnosed with SLE.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 8, 2022

First Posted

March 2, 2022

Study Start

November 3, 2021

Primary Completion

December 30, 2022

Study Completion

June 30, 2023

Last Updated

December 20, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations